High-dose Epirubicin Is Effective in Measurable Metastatic Prostate-cancer - a Phase-ii Study of the Eortc Genitourinary Group
(1995) European Journal of Cancer — Vol. 31A, n° 10, p. 1622-1626 (1995)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 557.86 KB
Details
- Authors
- Abstract
- 39 hormone-resistant prostate cancer patients with bidimensionally measurable metastatic lesions were given epirubicin 100 mg/m(2) intravenously every 3 weeks. One patient was ineligible and excluded from analyses. According to WHO criteria, 9 patients (24%) had a partial response, 16 patients (42%) had stable disease (including 3 patients (8%) with a partial response not confirmed 1 month later), 11 patients (29%) had progressive disease, and in 2 patients (5%) response was not evaluated. Toxicity was as expected. Fifty-five per cent of patients had WHO grade 3/4 toxicity for white blood cells, and 3% of patients grade 3 toxicity for platelets. Other toxicities included nausea and vomiting, mucositis and alopecia. 2 patients with pre-existing cardiac disease developed cardiotoxicity (1 grade 2, 1 grade 3). An attempt was made to correlate response with prostate specific antigen (PSA) measurements. A positive trend was seen, but 2 non-responding patients showed a > 50% decrease in value.
- Affiliations
Citations
Brausi, M., Jones, WG., Fossa, SD., Demulder, PHM., Droz, JP., Lentz, MA., Vanglabbeke, M., & Pawinski, A. (1995). High-dose Epirubicin Is Effective in Measurable Metastatic Prostate-cancer - a Phase-ii Study of the Eortc Genitourinary Group. European Journal of Cancer, 31A(10), 1622-1626. https://doi.org/10.1016/0959-8049(95)00193-M (Original work published 1995)